JW (Cayman) Therapeutics Co. Ltd
JWCTF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 48.9% | -17.8% | 0.8% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 61.2% | 47% | 50.4% | 50.4% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | $0 | $0 |
| Operating Expenses | $0 | -$0 | $0 | $0 |
| Operating Income | -$0 | $0 | -$0 | -$0 |
| % Margin | -110.6% | 346.6% | -285.1% | -464.1% |
| Other Income/Exp. Net | -$0 | -$1 | $0 | $0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -251.3% | -490.7% | -276.8% | -450.1% |
| EPS | -0.64 | -0.84 | -0.58 | -0.94 |
| % Growth | 23.8% | -44.8% | 38.3% | – |
| EPS Diluted | -0.64 | -0.84 | -0.58 | -0.94 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -75.3% | -260.7% | -236% | -261.8% |